Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
All vacancies for scientific directors at Germany's Max Planck Institutes will in future be advertised, and a world-wide search for new institute heads will be co-ordinated by central search commissions.
IBM's choice of protein folding as the focus of its project to develop the supercomputer Blue Gene is part of a strategy to position itself as a leader in computational biology.
A widely-heralded strategy paper arguing for a significantly higher public investment in German genomics research appears to have been put on hold, leading to concern that the move could threaten German efforts to catch up with other countries.
The Recombinant DNA Advisory Committee of the National Institutes of Health has been urged to recommend that gene-therapy researchers be required to report all ‘adverse events’ occuring during their trials.
French science minister Claude Allègre has asked the directors of France's main research agency to come up with more moderate changes to the agency's structure than those proposed last year.
Twenty five British schools have been piloting a new approach to teaching physics to 16 to 19 year olds that is already being hailed as successfully attracting back those who have been deserting the subject.
The target chamber from the Nova laser experiment at the Lawrence Livermore National Laboratory in California was last week shipped to France, where it will be use as part of a huge new laser facility to be built near Bordeaux.
China's desire to strengthen its scientific links with the Hong Kong Special Administrative Region has been confirmed by the announcement of 14 research projects funded jointly by the National Natural Science Foundation of China and the Research Grants Council of Hong Kong.
Gene therapy researchers using adenoviral vectors should apply stricter quality controls and more precise monitoring because of the ‘narrow window’ that separates their potential efficacy from toxicity, says a National Institutes of Health advisory panel.
